View on Pubmed.gov 19179415 | View on doi.org 10.1128/IAI.013...
Protection from pneumonic infection with burkholderia species by inhalational immunotherapy.
- Department of Microbiology, Immunology and Pathology, Colorado State University, Ft. Collins, CO 80523, USA.
Abstract
Burkholderia mallei and B. pseudomallei are important human pathogens and cause the diseases glanders and melioidosis, respectively. Both organisms are highly infectious when inhaled and are inherently resistant to many antimicrobials, thus making it difficult to treat pneumonic Burkholderia infections. We investigated whether it was possible to achieve rapid protection against inhaled Burkholderia infection by using inhaled immunotherapy. For this purpose, cationic liposome DNA complexes (CLDC), which are potent activators of innate immunity, were used to elicit the activation of pulmonary innate immune responses. We found that mucosal CLDC administration before or shortly after bacterial challenge could generate complete or nearly complete protection from inhalational challenge with 100% lethal doses of B. mallei and B. pseudomallei. Protection was found to be dependent on the CLDC-mediated induction of gamma interferon responses in lung tissues and was partially dependent on the activation of NK cells. However, CLDC-mediated protection was not dependent on the induction of inducible nitric oxide synthase, as assessed by depletion studies. We concluded that the potent local activation of innate immune responses in the lung could be used to elicit rapid and nonspecific protection from aerosol exposure to both B. mallei and B. pseudomallei.
References
Infect Immun. 2006 Nov;74(11):6300-9
Curr Opin Infect Dis. 2006 Oct;19(5):421-8
Infect Immun. 2007 Sep;75(9):4298-304
J Exp Med. 1984 Aug 1;160(2):600-5
Cited by 47 citations (total)
Journal Article
Evaluation of surrogate animal models of melioidosis.
Electronic publication date January 1, 2010
Jonathan Mark Warawa
Burkholderia pseudomallei is the Gram-negative bacterial pathogen responsible for the disease melioidosis. B. pseudomallei establishes disease in susceptible individuals through...
Journal Article
Local immune and microbiological responses to mucosal administration of a Liposome-TLR agonist immunotherapeutic in dogs.
Electronic publication date January 17, 2020
William Wheat [...] Steven Dow et al.
BACKGROUND
Non-specific immunotherapeutics have been evaluated previously in dogs, primarily for cancer treatment. However, there remains a need for a more...
Conflict of interest statement
MeSH
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
- •
- •
Substances
- •
- •
- •